Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-09

FDA Approved: EXPAREL — Supplemental Application (Pacira Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for EXPAREL (bupivacaine) filed by Pacira Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Exparel (liposomal bupivacaine)

Snippet

SUPPL AP for EXPAREL (BUPIVACAINE)